Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 5Leukemia, Myeloid, Acute 5Neoplasms 3Recurrence 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Colorectal Neoplasms 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharmacokinetics 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

Cyclophosphamide 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Triple Negative Breast Cancer × ALT-803 × Clear all
NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

ImmunityBio, Inc.

Phase 1/2 Terminated
3 enrolled 9 charts
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡